OR WAIT null SECS
December 21, 2020
A decision by the European Commission on conditional marketing authorization for the European Union’s first COVID-19 vaccine is expected soon.
December 18, 2020
FDA is expected to issue Emergency Use Authorization for Moderna’s vaccine, enabling immediate distribution.
December 15, 2020
Through the acquisition, Eli Lilly will have access to Prevail’s portfolio of clinical-stage and preclinical neuroscience assets.
December 14, 2020
EUA marks a milestone in COVID-19 vaccine development and is hailed as a turning point in pandemic fight.
Through the acquisition, AstraZeneca will work with Alexion’s R&D team to build up Alexion's pipeline of 11 molecules across more than 20 clinical-development programs in several indications.
December 11, 2020
Through the acquisition Gilead will gain access to Hepcludex (bulevirtide) for the treatment of chronic HDV infection in adults with compensated liver disease.
The acquisition will enhance Boehringer Ingelheim’s cancer cell-directed therapies portfolio and will complement its existing capabilities in antigen discovery and antibody and T-cell engager technologies.
Committee recommends Emergency Use Authorization of first mRNA-based COVID-19 vaccine; FDA approval is pending.
December 09, 2020
The company has received $500 million in funding from Sino Biopharmaceutical for further development, capacity expansion, and manufacturing of CoronaVac, its COVID-19 vaccine candidate.
December 08, 2020
Pfizer-BioNTech details its case for Emergency Use Authorization for "highly effective" COVID-19 vaccine.
